Literature DB >> 12359607

Electrophysiologic and phenotypic features of an autosomal cone-rod dystrophy caused by a novel CRX mutation.

Matthew A Lines1, Marc Hébert, Kerry E McTaggart, Sarah J Flynn, Matthew T Tennant, Ian M MacDonald.   

Abstract

PURPOSE: To reexamine a large Albertan family previously reported with a progressive cone dystrophy with variable phenotype and to map the disorder using molecular genetic techniques.
DESIGN: Observational case series. PARTICIPANTS: Twenty-nine subjects (10 affected) from four generations of a large kindred were clinically examined. Twenty-three of these individuals, as well as two unaffected spouses, were included in the molecular genetic study. Subject ages ranged from 17 to 91 years of age.
METHODS: Disease status and associated ocular abnormalities were assessed primarily by measurement of visual acuity, color vision, fundus photography, and both full-field and multifocal electroretinography (ERG and mfERG). Linkage of the disorder to the rhodopsin gene was studied using microsatellites. A mutational screen of the CRX gene was performed to identify coding sequence changes. MAIN OUTCOME MEASURES: Visual acuity and color discrimination were reduced in clinically affected individuals; full-field flash ERG was used to measure function of both cones and rods. mfERG and fundus photography allowed documentation of the observed macular changes.
RESULTS: We noted a variable, adult-onset macular dystrophy, progressing in some cases to a retinitis pigmentosa-like phenotype. Both photopic and scotopic full-field ERG amplitudes were reduced by approximately 50%, demonstrating involvement of both photoreceptor systems. A reduced b-wave amplitude with a relatively preserved a-wave was observed at both cone and rod levels. Macular involvement was confirmed by mfERG. The rhodopsin locus was excluded by haplotype analysis. A novel frameshift mutation was detected in exon III of the CRX retinal homeobox gene. ERG and molecular genetic findings were consistent with the reclassification of this disease as an autosomal dominant cone-rod dystrophy (CRD)
CONCLUSIONS: We report a novel CRX mutation causing autosomal dominant CRD. Observed ERG changes suggest that this mutation primarily impairs inner retinal function. Because retinal expression of CRX is limited to photoreceptors, this dysfunction may be the result of faulty photoreceptor communication with second-order retinal neurons. We propose misexpression of gated cation channels caused by altered CRX activity as one putative mechanism by which a sole photoreceptor defect may selectively impair neurotransmission without disrupting the upstream events of phototransduction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359607     DOI: 10.1016/s0161-6420(02)01187-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  5 in total

1.  Genetics and ARMD.

Authors:  Ian M MacDonald; Matthew A Lines
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

Review 2.  Mechanisms of blindness: animal models provide insight into distinct CRX-associated retinopathies.

Authors:  Nicholas M Tran; Shiming Chen
Journal:  Dev Dyn       Date:  2014-06-27       Impact factor: 3.780

3.  A novel CRX frameshift mutation causing cone-rod dystrophy in a Chinese family: A case report.

Authors:  Lihua Wang; Anhui Qi; Hong Pan; Beihong Liu; Jingjing Feng; Wei Chen; Binbin Wang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

4.  Characteristic Ocular Features in Cases of Autosomal Recessive PROM1 Cone-Rod Dystrophy.

Authors:  Frederick T Collison; Gerald A Fishman; Takayuki Nagasaki; Jana Zernant; J Jason McAnany; Jason C Park; Rando Allikmets
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

Review 5.  A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases.

Authors:  Sean L Johnson; Wei-Ling Tsou; Matthew V Prifti; Autumn L Harris; Sokol V Todi
Journal:  Front Mol Neurosci       Date:  2022-09-14       Impact factor: 6.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.